Jove
Visualize
Contact Us

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Commercialization of Cell Therapies: A CDMO Perspective.

Advances in experimental medicine and biology·2025
Same author

Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions.

Biotechnology reports (Amsterdam, Netherlands)·2023
Same author

The evaluation expression of non-coding RNAs in response to HSV-G47∆ oncolytic virus infection in glioblastoma multiforme cancer stem cells.

Journal of neurovirology·2022
Same author

Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells.

International journal of molecular sciences·2019
Same author

Computational fluid dynamics modeling, a novel, and effective approach for developing scalable cell therapy manufacturing processes.

Biotechnology and bioengineering·2019
Same author

Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers.

Frontiers in medicine·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Dec 21, 2025

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System
08:00

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System

Published on: May 14, 2015

32.2K

Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.

Mehdi Dashtban1, Krishna Morgan Panchalingam1, Mehdi Shafa1

  • 1Cell Therapy Process Department, Lonza Houston, Inc., Houston, TX, USA.

Methods in Molecular Biology (Clifton, N.J.)
|May 21, 2020
PubMed
Summary

Industrializing human induced pluripotent stem cells (iPSCs) for regenerative medicine requires overcoming manufacturing hurdles. This work focuses on developing cGMP-compliant processes, characterization, and scale-up technologies for affordable cell therapies.

Keywords:
3D computer-controlled bioreactorsCell therapyCommercializationInduced pluripotent stem cellsProcess developmentcGMP

More Related Videos

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

2.5K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.5K

Related Experiment Videos

Last Updated: Dec 21, 2025

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System
08:00

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System

Published on: May 14, 2015

32.2K
Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

2.5K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.5K

Area of Science:

  • Regenerative Medicine
  • Stem Cell Biology
  • Biomanufacturing

Background:

  • Human induced pluripotent stem cells (iPSCs) offer potential for cell replacement therapies in diseases like Parkinson's and diabetes.
  • Commercialization of iPSC therapies necessitates demonstrating safety, efficacy, and cost-effective industrial-scale manufacturing.
  • Current iPSC manufacturing processes are complex, lengthy, and require controlled differentiation of high-quality iPSCs.

Purpose of the Study:

  • To address key challenges in industrializing iPSC-derived cell therapy products.
  • To develop a current Good Manufacturing Practice (cGMP)-compliant iPSC manufacturing process.
  • To explore innovative technologies for scaling up iPSC processing.

Main Methods:

  • Development of a cGMP-compliant iPSC manufacturing process.
  • Establishment of a comprehensive iPSC characterization platform.
  • Assessment of long-term stability for cGMP-compliant iPSCs.
  • Implementation of innovative technologies for scale-up, including 3D computer-controlled bioreactors.

Main Results:

  • Summarizes efforts to overcome industrialization challenges for iPSC-derived cell therapies.
  • Focuses on establishing robust manufacturing, characterization, and stability protocols.
  • Highlights innovative scale-up solutions for iPSC processing.

Conclusions:

  • Addressing manufacturing obstacles is crucial for the commercial viability of iPSC-based regenerative medicine.
  • Development of cGMP-compliant processes and advanced technologies are key to affordable, large-scale iPSC therapies.
  • This work lays the groundwork for industrializing iPSC-derived cell therapies for widespread clinical application.